, Volume 52, Issue 3, pp 541–549 | Cite as

Elevated plasma tumor necrosis factor-α receptor 2 and resistin are associated with increased incidence of kidney function decline in Chinese adults

  • Gang Liu
  • Yueyi Deng
  • Liang Sun
  • Xingwang Ye
  • Pang Yao
  • Yao Hu
  • Feijie Wang
  • Yiwei Ma
  • Huaixing Li
  • Yong Liu
  • Qi SunEmail author
  • Xu LinEmail author
Original Article


Adipokines and inflammatory markers have been linked to kidney disease in animal models; however, evidence from prospective human studies is sparse. Recruited from Beijing and Shanghai in 2005, a total number of 2220 non-institutionalized Chinese individuals aged 50–70 years with baseline estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 were prospectively followed for 6 years. Plasma levels of resistin, retinol-binding protein 4 (RBP4), interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-α receptor 2 (TNF-R2) were determined at baseline. Kidney function decrease was assessed by measurements of eGFR over 6 years. Incident-reduced eGFR was defined as the onset of eGFR <60 mL/min/1.73 m2, according to the Modification of Diet in Renal Disease Study Equation for Chinese. During the 6 years of follow-up, 333 (15.0 %) participants had incident-reduced eGFR. Each 1 standard deviation elevated concentration of resistin [relative risk (RR) 1.10; 95 % CI 1.00–1.24] and TNFR-2 (RR 1.30; 95 % CI 1.13–1.49) at baseline were significantly associated with a higher risk of incident-reduced eGFR. Comparing the highest with the lowest quartiles, the RR of incident-reduced eGFR was 1.43 (95 % CI 1.01–2.03) for resistin and 2.03 (95 % CI 1.41–2.93) for TNF-R2 (both P trend < 0.05) after adjustment for baseline demographic characteristics, lifestyle behaviors, BMI, plasma lipid profile, hypertension, and diabetes. These associations remained significant when further controlling for levels of RBP4, IL-6, and CRP, none of which was significantly associated with the risk of incident-reduced eGFR. In this prospective cohort study, elevated levels of resistin and TNF-R2, but not other adipokines and inflammatory markers, were independently associated with a greater risk of kidney function decline in middle-aged and elderly Chinese.


Adipokines Inflammatory markers Prospective study Kidney function decline 



This study was supported by the Ministry of Science and Technology of China (2012CB524900 and 2013BAI04B03); the National Natural Science Foundation of China (81202272, 81321062, 30930081, and 81021002); ZY3-CCCX-3-2001, ZYSNXD-CC-HPGC-JD-003; the International Postdoctoral Exchange Fellowship Program 2015; the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences [2013KIP107]; and the SA-SIBS Scholarship Program.

Compliance with ethical standards

Conflict of interest

The manuscript has neither been published previously, nor under consideration for publication elsewhere. There is no conflict of interest in this study.

Supplementary material

12020_2015_807_MOESM1_ESM.docx (33 kb)
Supplementary material 1 (DOCX 32 kb)


  1. 1.
    L.X. Zhang, F. Wang, L. Wang et al., Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379, 815–822 (2012)CrossRefPubMedGoogle Scholar
  2. 2.
    A.S. Levey, R. Atkins, J. Coresh et al., Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 72, 247–259 (2007)CrossRefPubMedGoogle Scholar
  3. 3.
    A.K. Bello, E. Nwankwo, A.M. EL Nahas, Prevention of chronic kidney disease: a global challenge. Kidney Int. 68, S11–S17 (2005)CrossRefGoogle Scholar
  4. 4.
    J. Coresh, E. Selvin, L.A. Stevens et al., Prevalence of chronic kidney disease in the United States. JAMA 298, 2038–2047 (2007)CrossRefPubMedGoogle Scholar
  5. 5.
    Y. Xu, L.M. Wang, J. He et al., Prevalence and control of diabetes in Chinese adults. JAMA 310, 948–958 (2013)CrossRefPubMedGoogle Scholar
  6. 6.
    Chinese Center for Disease Control and Prevention, Major findings in chronic diseases and risk factors of national DSPs in 2010 (2011),
  7. 7.
    D. Gu, K. Reynolds, X. Duan et al., Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 46, 1190–1198 (2003)CrossRefPubMedGoogle Scholar
  8. 8.
    L. Fried, C. Solomon, M. Shlipak et al., Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J. Am. Soc. Nephrol. 15, 3184–3191 (2004)CrossRefPubMedGoogle Scholar
  9. 9.
    N.I. Tomosugi, S.J. Cashman, H. Hay et al., Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J. Immunol. 142, 3083–3090 (1989)PubMedGoogle Scholar
  10. 10.
    T. Bertani, M. Abbate, C. Zoja et al., Tumor necrosis factor induces glomerular damage in the rabbit. Am. J. Pathol. 134, 419–430 (1989)PubMedPubMedCentralGoogle Scholar
  11. 11.
    K.T. Mills, L.L. Hamm, A.B. Alper et al., Circulating adipocytokines and chronic kidney disease. PLoS One 8, e76902 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    C. Menzaghi, L. Salvemini, G. Fini et al., Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One 7, e38414 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    A. Shankar, L.P. Sun, B.E.K. Klein et al., Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 80, 1231–1238 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    L.D. Bash, T.P. Erlinger, J. Coresh, J. Marsh-Manzi, A.R. Folsom, B.C. Astor, Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Kidney Dis. 53, 596–605 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    J. Axelsson, P. Stenvinkel, Role of fat mass and adipokines in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 17, 25–31 (2008)CrossRefPubMedGoogle Scholar
  16. 16.
    H.J. Kim, N.D. Vaziri, Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am. J. Physiol. Renal Physiol. 298, F662–F671 (2010)CrossRefPubMedGoogle Scholar
  17. 17.
    J.S. Hiramoto, R. Katz, C.A. Peralta et al., Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Kidney Dis. 60, 225–232 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    C. Keller, R. Katz, M.J. Sarnak et al., Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol. Dial. Transpl. 25, 119–124 (2010)CrossRefGoogle Scholar
  19. 19.
    J.N. An, K.D. Yoo, J.H. Hwang et al., Circulating tumour necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction: a prospective cohort study. Nephrology 20, 552–559 (2015)CrossRefPubMedGoogle Scholar
  20. 20.
    A. Cabre, I. Lazaro, J. Girona et al., Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J. Intern. Med. 262, 496–503 (2007)CrossRefPubMedGoogle Scholar
  21. 21.
    A. Upadhyay, M.G. Larson, C.Y. Guo et al., Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol. Dial. Transpl. 26, 920–926 (2011)CrossRefGoogle Scholar
  22. 22.
    R. Kawamura, Y. Doi, H. Osawa et al., Circulating resistin is increased with decreasing renal function in a general Japanese population: the Hisayama Study. Nephrol Dial Transpl 25, 3236–3240 (2010)CrossRefGoogle Scholar
  23. 23.
    M. Pruijm, B. Ponte, P. Vollenweider et al., Not all inflammatory markers are linked to kidney function: results from a population-based study. Am. J. Nephrol. 35, 288–294 (2012)CrossRefPubMedGoogle Scholar
  24. 24.
    X.W. Ye, Z.J. Yu, H.X. Li, O.H. Franco, Y. Liu, X. Lin, Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J. Am. Coll. Cardiol. 49, 1798–1805 (2007)CrossRefPubMedGoogle Scholar
  25. 25.
    G. Zong, J.W. Zhu, L. Sun et al., Associations of erythrocyte fatty acids in the de novo lipogenesis pathway with risk of metabolic syndrome in a cohort study of middle-aged and older Chinese. Am. J. Clin. Nutr. 98, 319–326 (2013)CrossRefPubMedGoogle Scholar
  26. 26.
    Q.B. Qi, J.X. Wang, H.X. Li et al., Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur. J. Endocrinol. 159, 585–593 (2008)CrossRefPubMedGoogle Scholar
  27. 27.
    Q.B. Qi, Z.J. Yu, X.W. Ye et al., Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J. Clin. Endocr. Metab. 92, 4827–4834 (2007)CrossRefPubMedGoogle Scholar
  28. 28.
    X.W. Ye, O.H. Franco, Z.J. Yu et al., Associations of inflammatory factors with glycaemic status among middle-aged and older Chinese people. Clin. Endocrinol. 70, 854–862 (2009)CrossRefGoogle Scholar
  29. 29.
    F. Wang, P. Ye, L.M. Luo, W.K. Xiao, H.M. Wu, Association of risk factors for cardiovascular disease and glomerular filtration rate: a community-based study of 4925 adults in Beijing. Nephrol. Dial. Transpl. 25, 3924–3931 (2010)CrossRefGoogle Scholar
  30. 30.
    Y.C. Ma, L. Zuo, J.H. Chen et al., Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J. Am. Soc. Nephrol. 17, 2937–2944 (2006)CrossRefPubMedGoogle Scholar
  31. 31.
    A.S. Levey, K.U. Eckardt, Y. Tsukamoto et al., Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 67, 2089–2100 (2005)CrossRefPubMedGoogle Scholar
  32. 32.
    X.L. Kong, Y.C. Ma, J.H. Chen et al., Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol. Dial. Transpl. 28, 641–651 (2013)CrossRefGoogle Scholar
  33. 33.
    A.S. Levey, L.A. Stevens, C.H. Schmid et al., A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–607 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    L.D. Bash, J. Coresh, A. Kottgen et al., Defining incident chronic kidney disease in the research setting. Am. J. Epidemiol. 170, 414–424 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    T. Skov, J. Deddens, M.R. Petersen, L. Endahl, Prevalence proportion ratios: estimation and hypothesis testing. Int. J. Epidemiol. 27, 91–95 (1998)CrossRefPubMedGoogle Scholar
  36. 36.
    M.P. Reilly, M. Lehrke, M.L. Wolfe, A. Rohatgi, M.A. Lazar, D.J. Rader, Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111, 932–939 (2005)CrossRefPubMedGoogle Scholar
  37. 37.
    M. Bokarewa, I. Nagaev, L. Dahlberg, U. Smith, A. Tarkowski, Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 174, 5789–5795 (2005)CrossRefPubMedGoogle Scholar
  38. 38.
    C.M. Steppan, S.T. Bailey, S. Bhat et al., The hormone resistin links obesity to diabetes. Nature 409, 307–312 (2001)CrossRefPubMedGoogle Scholar
  39. 39.
    C. Chen, J. Jiang, J.M. Lu et al., Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 299, H193–H201 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Y. Cho, S.E. Lee, H.C. Lee et al., Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J. Am. Coll. Cardiol. 57, 99–109 (2010)CrossRefGoogle Scholar
  41. 41.
    P. Calabro, D.W. Chang, J.T. Willerson, E.T. Yeh, Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J. Am. Coll. Cardiol. 46, 1112–1113 (2005)CrossRefPubMedGoogle Scholar
  42. 42.
    E. Nehus, S. Furth, B. Warady, M. Mitsnefes, Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort. J. Pediatr. 161, 276–280 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    G. Hasegawa, K. Nakano, M. Sawada et al., Possible role of tumor-necrosis-factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 40, 1007–1012 (1991)CrossRefPubMedGoogle Scholar
  44. 44.
    M.A. Niewczas, T. Gohda, J. Skupien et al., Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 23, 507–515 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    A.C. Carlsson, T.E. Larsson, J. Helmersson-Karlqvist, A. Larsson, L. Lind, J. Arnlov, Soluble TNF receptors and kidney dysfunction in the elderly. J. Am. Soc. Nephrol. 25, 1313–1320 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    J.R. Bradley, TNF-mediated inflammatory disease. J. Pathol. 214, 149–160 (2008)CrossRefPubMedGoogle Scholar
  47. 47.
    T. Lawrence, The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1, a001651 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    V. Vielhauer, T.N. Mayadas, Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. Semin. Nephrol. 27, 286–308 (2007)CrossRefPubMedGoogle Scholar
  49. 49.
    G. Guo, J. Morrissey, R. McCracken, T. Tolley, S. Klahr, Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am. J. Physiol. 277, 766–772 (1999)Google Scholar
  50. 50.
    S. Vega, J. Benito-Leon, F. Bermejo-Pareja et al., Several factors influenced attrition in a population-based elderly cohort: neurological disorders in Central Spain Study. J. Clin. Epidemiol. 63, 215–222 (2010)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Gang Liu
    • 1
  • Yueyi Deng
    • 2
  • Liang Sun
    • 1
  • Xingwang Ye
    • 1
  • Pang Yao
    • 1
  • Yao Hu
    • 1
  • Feijie Wang
    • 1
  • Yiwei Ma
    • 1
  • Huaixing Li
    • 1
  • Yong Liu
    • 1
  • Qi Sun
    • 3
    • 4
    Email author
  • Xu Lin
    • 1
    Email author
  1. 1.From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological SciencesChinese Academy of Sciences, and University of Chinese Academy of SciencesShanghaiChina
  2. 2.Department of NephrologyLonghua Hospital Affiliated to Shanghai University of Traditional Chinese MedicineShanghaiChina
  3. 3.Department of NutritionHarvard School of Public HealthBostonUSA
  4. 4.Channing Division of Network Medicine, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations